Know Cancer

or
forgot password


Phase 3
18 Years
70 Years
Open (Enrolling)
Both
Hematological Disease

Thank you

Trial Information


Inclusion Criteria:



- Age 18-70

- Hematological disease

- Treatment with high-dose chemotherapy followed by autologous stem cell
transplantation

- Understanding of written German

Exclusion Criteria:

- Cardiorespiratory, metabolical, osteoarticular or immunological diseases which can be
aggravated by exercise

- Pathological stress-ECG at admission

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care

Outcome Measure:

VO2max

Outcome Time Frame:

At recruitment and after 3 weeks

Safety Issue:

No

Principal Investigator

Fernando Dimeo, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Charite University, Berlin, Germany

Authority:

Germany: Ethics Commission

Study ID:

EA4/029/09

NCT ID:

NCT00883961

Start Date:

December 2009

Completion Date:

September 2011

Related Keywords:

  • Hematological Disease
  • High-dose chemotherapy
  • Hematological neoplasties
  • Fatigue
  • Cancer
  • Exercise
  • Sport
  • Hematologic neoplastic disorders
  • Hematologic Diseases

Name

Location